Vascular Biogenics Ltd (NASDAQ:VBLT) reported on September 17th 2015, that the complete Phase 2 data on VB-111 in combination with Bevacizumab (Avastin(TM)) will be presented at the European Society for Medical Oncology’s (ESMO) European Cancer Congress 2015, being held September 25th-29th in Vienna, Austria.
“We look forward to this opportunity at ECC 2015 to present complete results from this important Phase 2 trial of VB-111 in rGBM,” stated Professor Dror Harats, CEO of VBL Therapeutics. “The presentation will include response rates in patients, as well as updated results on overall survival and response rate. We are excited to move forward with development of this first-in-class biologic agent and continue recruiting to our recently launched pivotal Phase 3 study in rGBM.”
VB-111 is a novel, intravenously-administered, next generation targeted anti-angiogenic agent that utilizes VBL’s proprietary Vascular Targeting System (VTS(TM)) to target endothelial cells in the tumor vasculature for cancer therapy. VB-111 contains a non-replicating adenovirus, a proprietary modified murine pre-proendothelin promoter (PPE-1-3x) and a Fas-Chimera transgene to angiogenic tumor blood vessels, leading to their apoptosis. VB-111 is the first agent based on transcriptional targeting of tumor endothelium to be assessed in a clinical trial.
Currently, the company has the Zacks Investment Research “BUY” rating right now that is why the stock is surging today.
This company’s stock is currently at $8.05 and has gained 17.52% in the Real-Time trading session. The market capitalization of the company is 143.02 Million with the total outstanding shares of 18.54 Million.
Infinity Pharmaceuticals Inc. (NASDAQ:INFI) reported on September 18th 2015 that the expansion of its pipeline with the addition of IPI-549, an orally administered immuno-oncology development candidate that selectively inhibits phosphoinositide-3-kinase gamma (PI3K-gamma), for the treatment of solid tumors. Preclinical data demonstrating the potential of IPI-549 to disrupt the immune-suppressive tumor microenvironment and enable a heightened anti-tumor immune response are being presented today at CRI-CIMT-EATI-AACR – The Inaugural International Cancer Immunotherapy Conference: Translating Science into Survival Meeting in New York City. IPI-549 was discovered at Infinity and is expected to enter Phase 1 clinical development in early 2016.
“Infinity is committed to developing first-in-class and best-in-class medicines, and the expansion of our pipeline with the addition of IPI-549 represents an important step toward fulfilling our vision of building a sustainable biopharmaceutical company that brings meaningful medicines to patients,” stated Vito Palombella, Ph.D., Infinity’s chief scientific officer. “Infinity’s ability to internally develop a selective PI3K-gamma inhibitor provides us with a unique opportunity to explore the impact that PI3K-gamma inhibition has on disrupting the tumor microenvironment. We look forward to initiating the first clinical study of IPI-549 in patients with solid tumors.”
“I have had the pleasure of collaborating with Infinity’s discovery team and am excited to have worked with IPI-549 in my laboratory,” Jedd Wolchok, M.D., Ph.D., chief of Melanoma and Immunotherapeutics Service, Lloyd J. Old/Ludwig Chair in Clinical Investigation Department of Medicine and Ludwig Center, at Memorial Sloan Kettering Cancer Center and the principal investigator for the planned Phase 1 clinical study of IPI-549. “IPI-549 is a novel, small molecule immuno-oncology agent, and I am looking forward to leading the Phase 1 study for this program.”
The stock surged 8.83% to reach at $9.98 right now in the real-time trade. The company has the market capitalization of 448.38 Million with the total outstanding shares of 49.19 Million.
CEL-SCI Corporation (NYSEMKT:CVM) on Tuesday September 1st, 2015 reported that in the month of August it has enrolled 19 patients in its ongoing Phase 3 trial of its investigational immunotherapy Multikine* (Leukocyte Interleukin, Injection) in patients with advanced primary squamous cell carcinoma of the oral cavity/soft palate, a type of head and neck cancer. Total patient enrollment is now 540 as of August 31, 2015 in the world’s largest Phase 3 study in head and neck cancer.
“A lower enrollment number in the month of August was expected since the majority of our clinical sites are in Europe and the month of August is known to be a primary vacation time in Europe. We expect enrollment in the fall to increase rapidly again with the goal of being completely enrolled by March of next year,” stated CEL-SCI Chief Executive Officer Geert Kersten.
A total of 880 patients are expected to be enrolled, through approximately 100 clinical centers in over 20 countries.
CEL-SCI Corporation (NYSEMKT:CVM) surged 9.89% in the real-time trade and is at 0.790 right now. The market capitalization of the company is 80.54 Million along with the total shares of 112.08 Million.